Ms. Iris Bincovich reports

INNOCAN PHARMA ANNOUNCES PROMISING TRANSLATIONAL EVIDENCE FROM A PAIN RELIEF STUDY OF REPEATED LPT-CBD ADMINISTRATION IN GOATS

Innocan Pharma Corp. has noted the publication of a research article titled "Liposomal-synthetic-cannabidiol: preliminary translational evidence of efficacy, tolerability and pharmacokinetics following repeated subcutaneous injections in two goats" in the peer-reviewed esteemed journal Frontiers in Pharmacology.

Two goats suffering from a chronic and disabling painful condition were treated with subcutaneous synthetic liposomal cannabidiol (LPT-CBD, five milligrams per kilogram) injections every six weeks for 10 months. Throughout the study, serial blood sampling was performed to assess CBD and its metabolite plasma concentrations and to evaluate hematological and biochemical profiles before and up to six weeks following each administration. Efficacy was assessed by the caregivers through quality of life weekly scoring, and adverse effects were monitored. Key findings include:

• Repeated LPT-CBD injections (seven injections per goat) maintained sustained CBD plasma concentrations consistent with a slow-release pharmacokinetic profile.
• Favourable drug tolerability was observed throughout the study with no recorded adverse events.
• In contrast to repeated oral CBD consumption in humans, this study showed that repeated LPT-CBD injections did not elevate liver enzyme markers typically associated with liver injury.
• Repeated administration of LPT-CBD resulted in sustained pain relief, improved mobility and enhanced quality of life, consistently maintained during the study period (10 months).

The results of this study offer clinically translatable information. LPT-CBD injections every six weeks are practical, have shown no adverse effects and provide long-term CBD plasma concentrations. Additionally, LPT-CBD demonstrated remarkable efficacy trends in pain control and well-being improvement for several weeks and can potentially provide similar results in people.

"The findings of this study highlight the sustained beneficial effects of LPT-CBD observed over 10 months of repeated administration said Prof. Chezy Barenholz, head of the advisory board. "LPT-CBD was designed for the treatment of chronic conditions through repeated monthly administrations, and this study provides promising translational evidence supporting this approach."

Dr. Eyal Kalo, vice-president of research and development, added: "This study demonstrates that repeated LPT-CBD administration, designed as a non-opioid chronic pain therapy, does not elevate liver enzymes, supporting a favourable long-term safety profile. By comparison, repeated oral CBD intake has been linked to elevated liver enzymes and potential liver injury. These results strengthen the evidence supporting the long-term safety of LPT-CBD in humans."

About Innocan Pharma Corp.

Innocan is an innovator in the pharmaceutical and wellness sectors. In the pharmaceutical sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing and prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high performance self-care and beauty products to promote a healthier lifestyle. Under this segment, Innocan carries on business through its 60-per-cent-owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted on-line sales.

We seek Safe Harbor.